DK1195605T3 - Metoder og kompositioner til screening af sphingosin modulatorer - Google Patents

Metoder og kompositioner til screening af sphingosin modulatorer

Info

Publication number
DK1195605T3
DK1195605T3 DK01402500T DK01402500T DK1195605T3 DK 1195605 T3 DK1195605 T3 DK 1195605T3 DK 01402500 T DK01402500 T DK 01402500T DK 01402500 T DK01402500 T DK 01402500T DK 1195605 T3 DK1195605 T3 DK 1195605T3
Authority
DK
Denmark
Prior art keywords
methods
screening
sphingosine
compositions
modulators
Prior art date
Application number
DK01402500T
Other languages
Danish (da)
English (en)
Inventor
Emmanuel Normant
Alirio Melendez
Olivier Casamitjana
Francois Moreau
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK1195605T3 publication Critical patent/DK1195605T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
DK01402500T 2000-09-29 2001-09-28 Metoder og kompositioner til screening af sphingosin modulatorer DK1195605T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402684A EP1195604A1 (de) 2000-09-29 2000-09-29 Verfahren und Zusammensetzungen zum Screenen von Modulatoren von Lipidkinasen

Publications (1)

Publication Number Publication Date
DK1195605T3 true DK1195605T3 (da) 2004-08-02

Family

ID=8173885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01402500T DK1195605T3 (da) 2000-09-29 2001-09-28 Metoder og kompositioner til screening af sphingosin modulatorer

Country Status (12)

Country Link
US (1) US6723525B2 (de)
EP (2) EP1195604A1 (de)
JP (1) JP2004509638A (de)
AT (1) ATE263373T1 (de)
AU (1) AU2001289939A1 (de)
CA (1) CA2423889A1 (de)
DE (1) DE60102539T2 (de)
DK (1) DK1195605T3 (de)
ES (1) ES2218351T3 (de)
PT (1) PT1195605E (de)
TR (1) TR200400941T4 (de)
WO (1) WO2002027318A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
JP4974297B2 (ja) * 2004-07-06 2012-07-11 パーキンエルマー・ヘルス・サイエンシズ・インコーポレーテッド 水和金属酸化物を用いるリン酸化分子の検出と単離のための方法と組成物
US20060270631A1 (en) * 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
CA2618715C (en) 2005-08-11 2015-05-19 Perkinelmer Las, Inc. Assay particles and methods of use
ATE555387T1 (de) * 2005-10-12 2012-05-15 Allergan Inc Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
EP2586874B1 (de) * 2010-06-28 2015-04-22 Daiichi Sankyo Company, Limited Verfahren zum screening auf s1p-lyase-hemmer mit kultivierten zellen
WO2013002248A1 (ja) 2011-06-28 2013-01-03 第一三共株式会社 リン酸エステル誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
ATE56096T1 (de) 1984-03-15 1990-09-15 Immunex Corp Test zur sofortigen feststellung von liganden, testsatz und seine herstellung.
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
WO1991008489A1 (en) * 1989-12-01 1991-06-13 Packard Instrument Company, Inc. Scintillation proximity radioimmunoassay using solid scintillator support body
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
AUPO900297A0 (en) * 1997-09-08 1997-10-02 Medvet Science Pty. Ltd. A method of modulating cellular activity
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
CA2329124A1 (en) * 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
BR9912501A (pt) * 1998-06-29 2001-05-02 Los Angeles Childrens Hospital Tratamento de distúrbios hiperproliferativos
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3

Also Published As

Publication number Publication date
TR200400941T4 (tr) 2004-06-21
US20020042091A1 (en) 2002-04-11
WO2002027318A1 (en) 2002-04-04
AU2001289939A1 (en) 2002-04-08
DE60102539T2 (de) 2005-04-07
ES2218351T3 (es) 2004-11-16
EP1195605A1 (de) 2002-04-10
DE60102539D1 (de) 2004-05-06
PT1195605E (pt) 2004-08-31
CA2423889A1 (en) 2002-04-04
ATE263373T1 (de) 2004-04-15
JP2004509638A (ja) 2004-04-02
US6723525B2 (en) 2004-04-20
EP1195605B1 (de) 2004-03-31
EP1195604A1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
EA200700702A1 (ru) Аналоги локсапина и способы их применения
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
ATE246938T1 (de) Anwendung der mesenchymalen stammzellen als immunsuppressiva
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
NO20050717L (no) Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
BR9509665A (pt) Composto composições e métodos
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
ATE361922T1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
DK1313721T3 (da) Ikke-imidazol-aryloxyalkylaminer som H3-receptorligander
ATE521397T1 (de) Attraktionssystem und verfahren zur bereitstellung einer attraktion
CY1108630T1 (el) Εξεταση βιοισοδυναμιας δια συνθεσεις οι οποιες περιεχουν σιδηρο
EA200801068A1 (ru) Производные четвертичного альфа-аминокарбоксамида в качестве модуляторов потенциалозависимых натриевых каналов
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
WO2005123043A3 (en) Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
ATE347611T1 (de) Automatischer apparat zum messen von wassertoxizität